莱维斯蒂利德A通过抑制葡萄糖代谢重编程和防止微质极化转移而产生神经保护作用:对帕金森病的影响
Mingjie Zhang1, Congyan Duan1, Weifang Lin1
1School of Medical Technology, Tianjin University of Traditional Chinese Medicine, 10 Poyanghu Road, West Area, Tuanbo New Town, Jinghai District, Tianjin 301617, China.
Molecules (Basel, Switzerland)
|February 24, 2024
概括
莱维斯蒂利德A (LA) 减少炎症,改变微质中的葡萄糖代谢,为帕金森病提供神经保护. 这种化合物通过调节微质极化和新陈代谢来显示治疗潜力.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 代谢过程中的代谢.
背景情况:
- 微质在帕金森病 (PD) 发病过程中发挥着关键作用.
- 糖解质重编程对于巨细胞炎症至关重要.
- 来自Angelica sinensis的Levistilide A (LA) 具有抗炎和神经保护作用.
研究的目的:
- 研究LA对微质诱导的炎症和葡萄糖代谢的影响.
- 探索LA对AMPK/mTOR通路的影响.
- 评估LA在体外和体内的神经保护潜力.
主要方法:
- 脂聚糖 (LPS) 诱导的微质模型.
- 分析炎症性细胞因子,ROS产生和信号通路 (AMPK/mTOR,NF-κB).
- 在体外和体内神经保护测定使用多巴胺基神经元.
主要成果:
- LA减少了M1促炎因素和微质中的ROS产量.
- 亚当素逆转了微质糖溶性重编程,并调节了AMPK/mTOR信号传递.
- 在体内,LA保护了多巴aminergic神经元,并降低了微质细胞的激活.
结论:
- 通过调节微质极化和葡萄糖代谢,LA显示出神经保护作用.
- 在帕金森病治疗中,LA具有治疗潜力.
- 准微质代谢是PD的一个有希望的策略.
相关概念视频
Parkinson's Disease: Treatment
268
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
268
Parkinson's Disease: Overview
546
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
546
Dipeptidyl Peptidase 4 Inhibitors
187
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
187
Neural Regulation
39.4K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.4K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
301
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
301


